Keros Therapeutics, Inc.
For the period ended Sep 30, 2025. Filed Nov 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 5, 2025
KROS$9.33+1.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
| COMMON STOCK$0.0001 PAR VALUE · ADDITIONALPAID-INCAPITAL · ACCUMULATEDDEFICIT · TOTAL STOCKHOLDERS’ EQUITY | |||||||
|---|---|---|---|---|---|---|---|
| SHARES · AMOUNT | |||||||
| As of December 31, 2024 | 40,554,705 | $4 | $1,140,328 | $(568,779) | $571,553 | ||
| Exercise of common stock options | 7,342 | — | 4 | — | 4 | ||
| Stock-based compensation | — | — | 8,863 | — | 8,863 | ||
| Net income (loss) | — | — | — | 148,451 | 148,451 | ||
| As of March 31, 2025 | 40,562,047 | $4 | $1,149,195 | $(420,328) | $728,871 | ||
| Exercise of common stock options | 53,367 | — | 17 | — | 17 | ||
| Stock-based compensation | — | — | 8,542 | — | 8,542 | ||
| Net income (loss) | — | — | — | (30,696) | (30,696) | ||
| As of June 30, 2025 | 40,615,414 | $4 | $1,157,754 | $(451,024) | $706,734 | ||
| Issuance of common stock under the employee stock purchase plan | 11,806 | — | 138 | — | 138 | ||
| Exercise of common stock options | 4,944 | — | 2 | — | 2 | ||
| Stock-based compensation | — | — | 3,986 | — | 3,986 | ||
| Net income (loss) | — | — | (7,280) | (7,280) | |||
| As of September 30, 2025 | 40,632,164 | $4 | $1,161,880 | $(458,304) | $703,580 | ||
| COMMON STOCK $0.0001 PAR VALUE · ADDITIONALPAID-INCAPITAL · ACCUMULATEDDEFICIT · TOTAL STOCKHOLDERS’ EQUITY | |||||||
| SHARES · AMOUNT | |||||||
| As of December 31, 2023 | 31,841,084 | $3 | $713,636 | $(381,426) | $332,213 | ||
| Issuance of common stock, net of underwriting discounts, commissions, and offering costs of $9,943 | 4,025,000 | — | 151,057 | — | 151,057 | ||
| Exercise of common stock options | 201,702 | — | 5,721 | — | 5,721 | ||
| Stock-based compensation | — | — | 8,070 | — | 8,070 | ||
| Net income (loss) | — | — | — | (43,114) | (43,114) | ||
| As of March 31, 2024 | 36,067,786 | $3 | $878,484 | $(424,540) | $453,947 | ||
| Issuance of common stock under the ATM agreement, net of commissions and offering costs of $164 | 14,068 | $— | $474 | $— | $474 | ||
| Exercise of common stock options | 87,704 | $— | 2,967 | $— | 2,967 | ||
| Stock-based compensation | — | $— | 8,785 | $— | 8,785 | ||
| Net income (loss) | — | $— | — | (45,257) | $(45,257) | ||
| As of June 30, 2024 | 36,169,558 | $3 | $890,710 | $(469,797) | $420,916 | ||
| Issuance of common stock under the ATM agreement, net of commissions and offering cost of $2,377 | 3,045,762 | 1 | 155,049 | — | $155,050 | ||
| Exercise of common stock options | 43,156 | — | 1,008 | — | 1,008 | ||
| Stock-based compensation | — | — | 8,817 | — | 8,817 | ||
| Net income (loss) | — | — | — | (52,956) | (52,956) | ||
| As of September 30, 2024 | 39,258,476 | $4 | $1,055,584 | $(522,753) | $532,835 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.